BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 28871563)

  • 1. Prognostic Value of the Age-Adjusted Charlson Comorbidity Index (ACCI) on Short- and Long-Term Outcome in Patients with Advanced Primary Epithelial Ovarian Cancer.
    Kahl A; du Bois A; Harter P; Prader S; Schneider S; Heitz F; Traut A; Alesina PF; Meier B; Walz M; Brueckner A; Groeben HT; Brunkhorst V; Heikaus S; Ataseven B
    Ann Surg Oncol; 2017 Nov; 24(12):3692-3699. PubMed ID: 28871563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.
    Suidan RS; Leitao MM; Zivanovic O; Gardner GJ; Long Roche KC; Sonoda Y; Levine DA; Jewell EL; Brown CL; Abu-Rustum NR; Charlson ME; Chi DS
    Gynecol Oncol; 2015 Aug; 138(2):246-51. PubMed ID: 26037900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of the age-adjusted Charlston co-morbidity index on peri-operative complications, adjuvant chemotherapy usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer.
    Phillips A; Singh K; Pounds R; Sundar S; Kehoe S; Nevin J; Elattar A; Balega J
    J Obstet Gynaecol; 2017 Nov; 37(8):1070-1075. PubMed ID: 28741395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery.
    Ataseven B; du Bois A; Reinthaller A; Traut A; Heitz F; Aust S; Prader S; Polterauer S; Harter P; Grimm C
    Gynecol Oncol; 2015 Sep; 138(3):560-5. PubMed ID: 26163893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.
    Kumar A; Janco JM; Mariani A; Bakkum-Gamez JN; Langstraat CL; Weaver AL; McGree ME; Cliby WA
    Gynecol Oncol; 2016 Jan; 140(1):15-21. PubMed ID: 26541980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal Muscle Attenuation (Sarcopenia) Predicts Reduced Overall Survival in Patients with Advanced Epithelial Ovarian Cancer Undergoing Primary Debulking Surgery.
    Ataseven B; Luengo TG; du Bois A; Waltering KU; Traut A; Heitz F; Alesina PF; Prader S; Meier B; Schneider S; Koch JA; Walz M; Groeben HT; Nina P; Brunkhorst V; Heikaus S; Harter P
    Ann Surg Oncol; 2018 Oct; 25(11):3372-3379. PubMed ID: 30069659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
    Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
    Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraoperative hypothermia during primary surgical cytoreduction for advanced ovarian cancer: risk factors and associations with postoperative morbidity.
    Long KC; Tanner EJ; Frey M; Leitao MM; Levine DA; Gardner GJ; Sonoda Y; Abu-Rustum NR; Barakat RR; Chi DS
    Gynecol Oncol; 2013 Dec; 131(3):525-30. PubMed ID: 24016410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-adjusted Charlson Comorbidity Index (ACCI) is a significant factor for predicting survival after radical gastrectomy in patients with gastric cancer.
    Lin JX; Huang YQ; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Huang ZN; Lin JL; Li P; Huang CM; Zheng CH
    BMC Surg; 2019 May; 19(1):53. PubMed ID: 31133008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV.
    Ataseven B; Grimm C; Harter P; Heitz F; Traut A; Prader S; du Bois A
    Gynecol Oncol; 2016 Feb; 140(2):215-20. PubMed ID: 26691222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of neutrophil to lymphocyte ratio as a prognostic indicator for epithelial ovarian cancer.
    Thavaramara T; Phaloprakarn C; Tangjitgamol S; Manusirivithaya S
    J Med Assoc Thai; 2011 Jul; 94(7):871-7. PubMed ID: 21774296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The age-adjusted Charlson comorbidity index as a predictor of survival in surgically treated vulvar cancer patients.
    Di Donato V; Page Z; Bracchi C; Tomao F; Musella A; Perniola G; Panici PB
    J Gynecol Oncol; 2019 Jan; 30(1):e6. PubMed ID: 30479090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of pelvic retroperitoneal invasion and distant nodal metastases in epithelial ovarian cancer.
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Pérez-Milán F; Ortiz-Quintana L
    Surg Oncol; 2014 Mar; 23(1):40-4. PubMed ID: 24183480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Success rate and safety of tumor debulking with diaphragmatic surgery for advanced epithelial ovarian cancer and peritoneal cancer.
    Saitou M; Iida Y; Komazaki H; Narui C; Matsuno K; Kawabata A; Ueda K; Tanabe H; Takakura S; Isonishi S; Sasaki H; Okamoto A
    Arch Gynecol Obstet; 2015 Mar; 291(3):641-6. PubMed ID: 25182215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Impact of Port-Site Metastasis After Diagnostic Laparoscopy for Epithelial Ovarian Cancer.
    Ataseven B; Grimm C; Harter P; Heikaus S; Heitz F; Traut A; Prader S; Kahl A; Schneider S; Kurzeder C; du Bois A
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):834-840. PubMed ID: 27406097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma.
    Al-Niaimi A; Dickson EL; Albertin C; Karnowski J; Niemi C; Spencer R; Shahzad MM; Uppal S; Saha S; Rice L; Nally AM
    Gynecol Oncol; 2016 Dec; 143(3):521-525. PubMed ID: 27693123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
    Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
    Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
    Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
    Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.